Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007

Emerging Infectious Diseases

Volumn 20, Issue 5, 2014, Pages 812-821

  Marks, Suzanne M ^a   Flood, Jennifer ^b   Seaworth, Barbara ^c,d   Hirsch Moverman, Yael ^e   Armstrong, Lori ^a   Mase, Sundari ^a   Salcedo, Katya ^b   Oh, Peter ^b   Graviss, Edward A ^f   Colson, Paul W ^e   Armitige, Lisa ^c,d   Revuelta, Manuel ^e   Sheeran, Kathryn ^c,d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^c TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^d UNIVERSITY OF TEXAS AT TYLER   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID PLUS RIFAMPICIN PLUS RIFABUTIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; EMPLOYMENT STATUS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LUNG LOBECTOMY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT OUTCOME; UNITED STATES; COMORBIDITY; DRUG COMBINATION; DRUG EFFECTS; EPIDEMIOLOGY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; HISTORY; OUTCOME ASSESSMENT; RISK FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HEALTH CARE COSTS; HISTORY, 21ST CENTURY; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

EID: 84898906246     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2005.131037     Document Type: Article

References (21)

1. Munsiff SS, Ahuja SD, Li J, Driver CR. Public-private collaboration for multidrug-resistant tuberculosis control in New York City. Int J Tuberc Lung Dis. 2006;10:639-48.
2. Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura LM, Schecter G, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis. 2005;40:968-75. http://dx.doi.org/10.1086/428582
3. Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA. 2008;300:2153-60. http://dx.doi.org/10.1001/ jama.300.18.2153
4. Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis. 2008;47:450-7. http://dx.doi.org/10.1086/590009
5. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8:1012-6.
6. Althomsons SP, Cegielski JP. Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR TB is bad enough. Int J Tuberc Lung Dis. 2012;16:1331-4. http://dx.doi. org/10.5588/ijtld.11.0812
7. Centers for Disease Control and Prevention. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recomm Rep. 2003;52(RR-11):1-80.
8. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516-28. http://dx.doi.org/10.1183/09031936.00073611
9. Centers for Medicare & Medicaid Services. Operating cost to charge ratios (OPCCR). FY2005 Impact file (inpatient prospective payment system) 2005 [cited 2010 May 12]. http://www.cms.gov/ Medicare/Medicare-Fee-for-Service-Payment/PCPricer/index. html?redirect=/pcpricer
10. Bureau of Labor Statistics. Consumer Price Index-all urban consumers, medical care. Series ID CUUR0000SAM [cited 2012 Feb 21]. http://data.bls.gov/cgi-bin/srgate
11. Centers for Medicare & Medicaid Services. Medicare geographic adjustment factors [cited 2010 May 12]. http://www.cms.gov/ Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Geographic-Variation/GV_PUF.html
12. Grosse SD. Appendix I: productivity loss tables. In: Haddix AC, Teutsch SM, Corso PS, editors. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd ed. New York: Oxford University Press; 2003. p. 245-57.
13. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE. 2009;4:e6914. http://dx.doi. org/10.1371/journal.pone.0006914
14. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-61. http://dx.doi.org/10.1016/S1473-3099(09)70041-6
15. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51:6-14. http://dx.doi.org/10.1086/653115
16. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data metaanalysis of 9,153 patients. PLoS Med. 2012;9: e1001300. http:// dx.doi.org/10.1371/annotation/230240bc-bcf3-46b2-9b21-2e6e584f7333
17. Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;380:1406-17. http://dx.doi.org 10.1016/S0140-6736(12)60734-X
18. Banerjee R, Allen J, Lin SYG, Westenhouse J, Desmond E, Schecter GF, et al. Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California. J Clin Microbiol. 2010;48:3779-81. http://dx.doi.org/10.1128/JCM.01236-10
19. Hutchinson AB, Farnham PG, Duffy N, Wolitski RJ, Sansom SL, Dooley SW, et al. Return on public health investment: CDC's expanded HIV testing initiative. J Acquir Immune Defic Syndr. 2012;59:281-6. PMID: 22067662 doi: 10.1097/QAI.0b013 e31823e5bee
20. Campbell JD, Ramsey SD. The costs of treating breast cancer in the U.S.: a synthesis of published evidence. Pharmacoeconomics. 2009;27:199-209. http://dx.doi.org/10.2165/00019053-200927030-00003
21. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City-turning the tide. N Engl J Med. 1995;333:229-33.